SynthesisFrontiers in medicine2026
Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To conduct a scoping review mapping the extent, nature, and consistency of available evidence regarding the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on kidney function, proteinuria, kidney outcomes, and mortality in patients with IgA nephropathy (IgAN). Methods: This scoping review was conducted in accordance with the PRISMA-ScR guidance. Randomized controlled trials (RCTs) including patients with IgAN were identified to characterize high-level efficacy signals. Observational studies, real-world cohorts, and mechanistic investigations were additionally included to contextualize and extend the randomized evidence. Findings were mapped across five predefined outcome domains: acute eGFR dip, chronic eGFR slope, proteinuria reduction, kidney outcomes, and mortality. Results: Two large randomized controlled trials, DAPA-CKD and EMPA-KIDNEY, provided randomized evidence supporting kidney-protective effects of SGLT2 inhibitors in IgAN subgroups. Complementary observational and real-world studies consistently demonstrated clinically meaningful reductions in proteinuria, stabilization of kidney function trajectories, and mechanistic patterns linking early hemodynamic responses with longer-term renal benefit. Mortality data specific to IgAN remain limited; however, indirect evidence from broader CKD populations suggests biological plausibility for cardiovascular and survival benefits. Conclusion: The available evidence supporting SGLT2 inhibitors in IgA nephropathy is broad, convergent across study designs, and mechanistically coherent. Although disease-specific randomized trials remain limited, consistent signals from randomized, observational, and mechanistic evidence support the role of SGLT2 inhibitors as kidney-protective therapy in IgAN and highlight priorities for future IgAN-focused research. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=630522, identifier (CRD42025630522).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.